BioLineRx highlights Phase 1/2a GLIX1 trial in recurrent high-grade glioma at SNO meeting
Bitget2026/10/08 11:03BioLineRx disclosed two GLIX1 posters scheduled for the Society for Neuro-Oncology annual meeting in Philadelphia on Nov. 13, 2026. Preclinical work will be presented, describing broad anti-tumor activity in multiple glioblastoma models, including treatment-resistant disease. A separate poster will outline the design of an ongoing Phase 1/2a trial of oral GLIX1 in recurrent or progressive high-grade glioma. GLIX1 is positioned as the company’s lead development program, extending its focus beyond its marketed stem-cell mobilization product. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioLineRX Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610080700PR_NEWS_USPR_____LN65857) on October 08, 2026, and is solely responsible for the information contained therein.
- BioLineRx disclosed two GLIX1 posters scheduled for the Society for Neuro-Oncology annual meeting in Philadelphia on Nov. 13, 2026.
- Preclinical work will be presented, describing broad anti-tumor activity in multiple glioblastoma models, including treatment-resistant disease.
- A separate poster will outline the design of an ongoing Phase 1/2a trial of oral GLIX1 in recurrent or progressive high-grade glioma.
- GLIX1 is positioned as the company’s lead development program, extending its focus beyond its marketed stem-cell mobilization product.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
